• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home StudyGraphics

#VisualAbstract: Dapagliflozin does not reduce albuminuria in patients with heart failure and type 2 diabetes (DAPPER study)

byWinnie LiuandMinjee Kim
December 1, 2023
in StudyGraphics
Reading Time: 1 min read
#VisualAbstract: Dapagliflozin does not reduce albuminuria in patients with heart failure and type 2 diabetes (DAPPER study)
Share on FacebookShare on TwitterShare on LinkedIn

Click here to read this study in the NEJM (New England Journal of Medicine). 

FDA approvedFor type 2 diabetes: Onswik (insulin efsitora alfa-gobe), Sep 23, 2026→

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc. 

RELATED REPORTS

VS-041 reduced NT-proBNP after 28 days in a phase 1c HFpEF trial

2MM: Pharma Roundup – First DNA therapy approved which could reduce airway surgeries, novel siRNA targets dual lipid pathways, GLP-1s outperform metformin in prediabetes, and Zolgensma tumor risks under FDA review

Tags: albuminuriadapagliflozindiabetesheart failuretype 2 diabetes
Previous Post

Several exercise modalities improve sleep quality in patients with sleep disorders

Next Post

#VisualAbstract: Intravenous Levothyroxine Does Not Increase the Number of Heart Transplants in Unstable Brain-Dead Potential Heart Donors

RelatedReports

A heart on one side of a scale balances against a tablet on the other, suggesting evaluation of heart health and medication in cardiology.
2MM Trial Briefs

VS-041 reduced NT-proBNP after 28 days in a phase 1c HFpEF trial

November 13, 2026
A variety of pharmaceutical items including a vial, capsule, molecule model, pill blister pack, petri dish with a pipette, and a graph, symbolizing drug development.
Pharma Roundup

2MM: Pharma Roundup – First DNA therapy approved which could reduce airway surgeries, novel siRNA targets dual lipid pathways, GLP-1s outperform metformin in prediabetes, and Zolgensma tumor risks under FDA review

November 9, 2026
A balance scale with a syringe on one side and silhouettes of varying body sizes on the other, symbolizing weight management and GLP-1 medications.
2MM Trial Briefs

In topline phase 3 results, retatrutide lowered A1C more and reduced weight more than semaglutide 2 mg at 80 weeks

October 29, 2026
A man is sleeping on his side with a caution symbol and tape beside him, while lung images are in the background, suggesting a focus on sleep and respiratory health.
Cardiology

Increased rapid eye movement (REM) sleep is associated with lower risks of several chronic diseases

September 23, 2026
Next Post
#VisualAbstract: Intravenous Levothyroxine Does Not Increase the Number of Heart Transplants in Unstable Brain-Dead Potential Heart Donors

#VisualAbstract: Intravenous Levothyroxine Does Not Increase the Number of Heart Transplants in Unstable Brain-Dead Potential Heart Donors

Different types of graphs and charts

A Begginer's Guide to Understanding Odds Ratios, Confidence Intervals, and P-values

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial

2 Minute Medicine Rewind December 3, 2023

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • In a randomized sham-controlled trial, acupoint thread embedding produced a between-group difference in change from baseline of 1.8 kg at 12 weeks and 3.0 kg at 24 weeks in Chinese women with overweight or obesity
  • PROT-001 was generally safe and well tolerated in a phase 1 study of healthy volunteers with AL amyloidosis
  • 2MM: AI Roundup- PTSD Prediction, Gait as a Biomarker, Faster Cardiac MRI, and Perinatal Mental Health Chatbots [November 12th, 2026]
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.